Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a <i>post hoc</i> integrated analysis of patients with moderate‐to‐severe plaque psoriasis-Reference-Cited by-同舟云学术

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis

Published:2022-03-17 Issue:6 Volume:36 Page:855-865
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Gooderham M.¹^ORCID,Pinter A.²^ORCID,Ferris L.K.³,Warren R.B.⁴,Zhan T.⁵^ORCID,Zeng J.⁵,Soliman A.M.⁵,Kaufmann C.⁵,Kaplan B.⁵,Photowala H.⁵,Strober B.⁶^ORCID

Affiliation:

1. SKiN Centre for Dermatology Probity Medical Research and Queen’s University Peterborough ON Canada

2. Department of Dermatology University Hospital Frankfurt am Main Frankfurt am Main Germany

3. Department of Dermatology University of Pittsburgh Pittsburgh PA USA

4. The Dermatology Centre Salford Royal NHS Foundation Trust Manchester NIHR Biomedical Research Centre University of Manchester Manchester UK

5. AbbVie, Inc. North Chicago IL USA

6. Yale University, New Haven, CT and Central Connecticut Dermatology Research CromwellCTUSA

Funder

AbbVie

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.18010

Reference32 articles.

1. Psoriasis

2. The global burden of psoriatic skin disease

3. The immunogenetics of Psoriasis: A comprehensive review

4. Psoriasis Prevalence and Severity by Expert Elicitation

5. Discapacidad acumulada en el transcurso vital: la cicatriz de la psoriasis en la vida del paciente

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial;Dermatology and Therapy;2024-08-17

2. Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials;Dermatology and Therapy;2024-08-17

3. Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study;Dermatology and Therapy;2024-05

4. Therapy of moderate-to-severe plaque psoriasis;Meditsinskiy sovet = Medical Council;2024-03-06

5. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry;Journal of the American Academy of Dermatology;2024-01